[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY) Stock Moves -0.55%: What You Should Know",
    "summary": "In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $57.68, denoting a -0.55% change from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=1e3fe7d8bef307bb2023d127d1fc91401e17adcc2e689205ecaaa9d3ceecf0db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735339519,
      "headline": "Bristol Myers Squibb (BMY) Stock Moves -0.55%: What You Should Know",
      "id": 132181683,
      "image": "https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $57.68, denoting a -0.55% change from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=1e3fe7d8bef307bb2023d127d1fc91401e17adcc2e689205ecaaa9d3ceecf0db"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2",
    "summary": "PRINCETON, N.J., December 27, 2024--US FDA Approves Opdivo Qvantig Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo Indications",
    "url": "https://finnhub.io/api/news?id=d27305fc870a05290580e88572340bd4c35463f899389efe4adcd3bc438aaf93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735339020,
      "headline": "U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2",
      "id": 132181684,
      "image": "https://media.zenfs.com/en/business-wire.com/2621d8082f6196a17c677b0b0bad1d78",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., December 27, 2024--US FDA Approves Opdivo Qvantig Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo Indications",
      "url": "https://finnhub.io/api/news?id=d27305fc870a05290580e88572340bd4c35463f899389efe4adcd3bc438aaf93"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives FDA Approval for Cancer Treatment",
    "summary": "By Connor Hart Bristol Myers Squibb received approval from the Food and Drug Administration for its treatment of certain cancers. The Princeton, N.J., company said Friday approval for the...",
    "url": "https://finnhub.io/api/news?id=ec29bf9867af3cbaec6310c046eb2f631cc442b13f3f6164fdcc47946229ab10",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735323193,
      "headline": "Bristol Myers Squibb Receives FDA Approval for Cancer Treatment",
      "id": 132180563,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "By Connor Hart Bristol Myers Squibb received approval from the Food and Drug Administration for its treatment of certain cancers. The Princeton, N.J., company said Friday approval for the...",
      "url": "https://finnhub.io/api/news?id=ec29bf9867af3cbaec6310c046eb2f631cc442b13f3f6164fdcc47946229ab10"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approval of Injectable Opdivo: Bristol Myers Squibb Fights Off Patent Cliff Concerns",
    "summary": "FDA approves injectable Opdivo, boosting Bristol Myers Squibb's market position ahead of patent expiration",
    "url": "https://finnhub.io/api/news?id=2f05db80acd87a28ef1157c0472fe30e84f9a3dce24e6e6d3c0fd28b4d820580",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735321927,
      "headline": "FDA Approval of Injectable Opdivo: Bristol Myers Squibb Fights Off Patent Cliff Concerns",
      "id": 132178401,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/cace2ec75f6cb78f5be8cd680d00a092",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "FDA approves injectable Opdivo, boosting Bristol Myers Squibb's market position ahead of patent expiration",
      "url": "https://finnhub.io/api/news?id=2f05db80acd87a28ef1157c0472fe30e84f9a3dce24e6e6d3c0fd28b4d820580"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Opdivo Qvantig?? (nivolumab and Hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo®? (Nivolumor Opdivo) Indications",
    "summary": "Bristol Myers Squibb announced that the U.S. Food and Drug Administration granted approval for Opdivo Qvantig? injectionfor subcutaneous use, a combination product of nivolumabco-formulated with...",
    "url": "https://finnhub.io/api/news?id=aec040ba494fdb713d7cb435bc80a3a52a2176e080ffd68e2cde223bbe8c8a13",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735321020,
      "headline": "Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Opdivo Qvantig?? (nivolumab and Hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo®? (Nivolumor Opdivo) Indications",
      "id": 132180672,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb announced that the U.S. Food and Drug Administration granted approval for Opdivo Qvantig? injectionfor subcutaneous use, a combination product of nivolumabco-formulated with...",
      "url": "https://finnhub.io/api/news?id=aec040ba494fdb713d7cb435bc80a3a52a2176e080ffd68e2cde223bbe8c8a13"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)",
    "summary": "The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo.  Opdivo is part of a class of drugs called PD-1 inhibitors, which enhance the immune system's ability to fight cancer by removing its natural brakes.",
    "url": "https://finnhub.io/api/news?id=8ddf1f2d55da9ef2146f09bc356af59ab979f7d3e790c3d0557ed7263f363f94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735317324,
      "headline": "FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)",
      "id": 132307523,
      "image": "https://media.zenfs.com/en/reuters-finance.com/7dec6bb119eb7225b49c6859ac11770a",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo.  Opdivo is part of a class of drugs called PD-1 inhibitors, which enhance the immune system's ability to fight cancer by removing its natural brakes.",
      "url": "https://finnhub.io/api/news?id=8ddf1f2d55da9ef2146f09bc356af59ab979f7d3e790c3d0557ed7263f363f94"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo",
    "summary": "The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo.  Opdivo is part of a class of drugs called PD-1 inhibitors, which enhance the immune system's ability to fight cancer by removing its natural brakes.",
    "url": "https://finnhub.io/api/news?id=673cee95e85be58cb12ba60b358faf130913f54592855b7b471d41f92ec58c89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735317324,
      "headline": "FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo",
      "id": 132307521,
      "image": "https://media.zenfs.com/en/reuters.com/7dec6bb119eb7225b49c6859ac11770a",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo.  Opdivo is part of a class of drugs called PD-1 inhibitors, which enhance the immune system's ability to fight cancer by removing its natural brakes.",
      "url": "https://finnhub.io/api/news?id=673cee95e85be58cb12ba60b358faf130913f54592855b7b471d41f92ec58c89"
    }
  },
  {
    "ts": null,
    "headline": "Duvakitug And Teva's Growth: A Game Changer In Pharma",
    "summary": "Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here to find out why TEVA is a Buy.",
    "url": "https://finnhub.io/api/news?id=f932524cce0ab7e6732fb2bdfb867eccfcc2050d50d49631a3b1c7b1033d3814",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735312889,
      "headline": "Duvakitug And Teva's Growth: A Game Changer In Pharma",
      "id": 132178012,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1816401471/image_1816401471.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here to find out why TEVA is a Buy.",
      "url": "https://finnhub.io/api/news?id=f932524cce0ab7e6732fb2bdfb867eccfcc2050d50d49631a3b1c7b1033d3814"
    }
  },
  {
    "ts": null,
    "headline": "US FDA approves injectable form of Bristol Myers' Opdivo",
    "summary": "The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. ...",
    "url": "https://finnhub.io/api/news?id=202c96c0863fa2bc08d8786206bc61128daaa5d48bd96bcda47189b2b9bb19b0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735299324,
      "headline": "US FDA approves injectable form of Bristol Myers' Opdivo",
      "id": 132175169,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. ...",
      "url": "https://finnhub.io/api/news?id=202c96c0863fa2bc08d8786206bc61128daaa5d48bd96bcda47189b2b9bb19b0"
    }
  }
]